Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Non-phase study NCT07051005

Feasibility of a Tailored Online Self-compassion Intervention

Feasibility of a Tailored Online Self-compassion Intervention — Recruiting • Non-phase study • Diabetes / Metabolic • NCT07051005.

📅 25 Mar 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07051005
Sponsor
Canterbury Christ Church University
Start
2025-06-18
ClinicaliQ Trial Snapshot
  • Feasibility of a Tailored Online Self-compassion Intervention — Recruiting • Non-phase study • Diabetes / Metabolic • NCT07051005.
  • The goal of this clinical trial is to examine the feasibility and acceptability of an online programme that is based on Compassionate Mind Training (CMT) over four-weeks. The programme intends to share information and strategies to reduce diabetes distress, self-criticism, and shame,….
  • Sponsor: Canterbury Christ Church University.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The goal of this clinical trial is to examine the feasibility and acceptability of an online programme that is based on Compassionate Mind Training (CMT) over four-weeks. The programme intends to share information and strategies to reduce diabetes distress, self-criticism, and shame, and improve physical health in people who have Type 1 and Type 2 Diabetes Mellitus. Lead Sponsor: Canterbury Christ Church University Start Date: 2025-06-18 Primary Completion: 2026-05-01

Eligibility Snapshot
  • : * 18 years old or older. * Diagnosed with Type 1 or Type 2 diabetes by a clinician in the NHS more than one year ago. * Self-managing theircondition. * Identified by their NHS team as needing support with their mental health due to diabetes-related distress.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Semaglutide for Managing Overweight and Obesity (NICE TA875)
Diabetes / Metabolic · 27 Mar 2026
Initiate semaglutide only in specialist obesity services or via shared care with clear primary-secondary care protocols for adults with BMI ≥30 kg/m²…
View guideline →
Guideline
Type 1 Diabetes in Adults: Diagnosis and Management (NICE NG17)
Diabetes / Metabolic · 25 Mar 2026
Offer multiple daily injection (MDI) basal-bolus insulin regimen as first-line treatment for all adults with type 1 diabetes, with continuous subcutaneous insulin…
View guideline →
Guideline
Tirzepatide for Managing Overweight and Obesity (NICE TA1026)
Diabetes / Metabolic · 27 Mar 2026
Prescribe tirzepatide to adults with BMI ≥35 kg/m² or BMI 30–34.9 kg/m² with weight-related comorbidities, initiating treatment in specialist weight management services…
View guideline →
Clinical Brief
Mental health support to be offered to people with diabetes in UK first
Diabetes / Metabolic · BBC Health · 17 Apr 2026
People with diabetes have double the risk of depression compared to the general population, highlighting the need for integrated mental health screening…
View brief →
Clinical Brief
GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse
Diabetes / Metabolic · MHRA · 24 Oct 2024
Healthcare professionals are reminded to inform patients about the common and serious side effects associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs). This…
View brief →
Podcast
GLP-1 Agonists: Semaglutide, Tirzepatide and the Cardiovascular Revolution
Diabetes / Metabolic · 00:15:32 · 03 Apr 2026
GLP-1 receptor agonists mimic gut-derived GLP-1: they increase glucose-dependent insulin release, suppress glucagon and slow gastric emptying. Semaglutide is a once-weekly GLP-1…
Listen →